Cascadian Therapeutics, Inc. - 10-K filing on 2015-03-10

Note 7 - Share-based Compensation (Tables)

12 Months Ended

Dec. 31, 2014

Options	Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term		Aggregate Intrinsic Value
In Canadian dollars ($CDN):
Outstanding at January 1, 2014		687,533		$	7.53
Granted		—			—
Exercised		—			—
Forfeited		(6,666	)		8.64
Expired		(508,332	)		7.42
Outstanding at December 31, 2014		172,535		$	7.80		0.37	$	—
Vested or expected to vest at December 31, 2014		172,535		$	7.80		0.37	$	—
Vested and exercisable at December 31, 2014		172,535		$	7.80		0.37	$	—

In US dollars ($US):
Outstanding at January 1, 2014		3,727,500		$	3.41
Granted		1,444,500			1.82
Exercised		(6,000	)		1.10
Forfeited		(71,000	)		3.76
Expired		(50,000	)		1.83
Outstanding at December 31, 2014		5,045,000		$	2.97		6.01	$	543,010
Vested or expected to vest at December 31, 2014		4,938,695		$	2.99		5.97	$	529,330
Vested and exercisable at December 31, 2014		2,172,303		$	3.96		4.35	$	186,549

	2014			2013			2012
Weighted average grant-date fair value per stock option $US	$	1.24		$	1.26		$	3.41
Expected dividend rate		—			—			—
Expected volatility		78.67	%		86.53	%		84.68	%
Risk-free interest rate		1.65	%		1.90	%		0.89	%
Expected life of options in years		5.82			6.0			6.0

Restricted Share Units	Restricted Share Units			Weighted Average Fair Value per Unit
Outstanding at January 1, 2014		191,613		$	1.76
Granted		81,695			3.06
Converted		(110,104	)		3.47
Outstanding at December 31, 2014		163,204		$	1.90
Expected to vest at December 31, 2014		163,204		$	1.90